Experimental stem cell injection targets autism Self-Harm

NCT ID NCT07433517

Not yet recruiting Disease control Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial will test a new treatment called VGN-Ex05e, made from human embryonic stem cells, for children and teens with autism who have severe, treatment-resistant self-injury or aggression. The treatment is injected directly into a brain area linked to behavior. Only 6 participants will be enrolled, and the main goal is to check safety and tolerability, not effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VGN-Ex05e (nerve cells from human embryonic stem cells)
What this could lead to: If it works, this could point toward a new way to reduce severe self-injury and aggression in some people with autism.
What could go wrong: This is a very early, tiny trial (6 people) focused on safety, not proof of benefit. The brain injection carries risks, and results may not apply to most people with autism.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autism spectrum disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTISM SPECTRUM DISORDER

More trials for these conditions

Other studies related to the condition(s) this trial covers.